Applications of Rasagiline Mesylate in Industrial Manufacturing

Rasagiline Mesylate, manufactured under stringent pharmaceutical standards at our facility, forms a critical API in specialty sectors of the pharmaceutical industry. We supply to manufacturers engaging in well-defined downstream applications, supporting clinical and commercial product manufacturing. Below, we detail core application scenarios and integration points in industrial operations.

1. Formulation of Antiparkinsonian Oral Solid Dosage Pharmaceuticals

Commercial pharmaceutical companies widely incorporate this raw material in the formulation of oral solid dosage forms—primarily tablets—intended for treatment regimens targeting Parkinson’s disease. The API’s use profile is strictly controlled and validated during process development by formulation chemists, with process steps aligned to regulatory pre-approval inspections. Production integrates precise API addition during granulation or direct compression, tied to PK/PD data and bioequivalence considerations highlighted in the dossier.

Industry compliance standards

• Current Good Manufacturing Practice (cGMP) under 21 CFR Parts 210 & 211 (US FDA)
• ICH Q7 – Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) and United States Pharmacopeia (USP) monographs for API quality
• WHO GMP and PIC/S standards for export regulated regions

Typical usage ratio

• Final tablet formulations contain 0.5 – 1 mg per unit dose. API addition as 0.1–0.3% w/w in total blend, adjusted according to target strength and tableting yield factors.

Downstream process integration

• Addition occurs during the blending stage, directly before wet or dry granulation for tablets. In direct compression technology, dosing follows inline content uniformity verification for batch release. QC sampling and HPLC based assay confirm actual API content at this stage.

Final product types

• Parkinson’s treatment tablets in single- or multi-dose packaging
• Film-coated and uncoated solid oral dosage forms for hospital and pharmacy supply chains

2. Production of Antiparkinsonian Orodispersible Films (ODF)

ODF manufacturers in regulated markets adopt this API for patient-centric quick-dissolving films, improving patient compliance, particularly for geriatric use. Manufacturers incorporate the active compound into hydrocolloid and polymer-based matrix systems during solvent-casting or hot-melt extrusion. The process demands precision in homogeneity and mechanical strength, validated against disintegration and dissolution kinetics under simulated physiological conditions.

Industry compliance standards

• US FDA’s Guidance for Industry: Orally Disintegrating Tablets and Films
• ICH Q8 – Pharmaceutical Development
• Ph. Eur. 2.9.1 (Disintegration of Tablets and Films)
• Japanese Pharmacopoeia criteria for solid oral dispersions (if manufactured for Japan)

Typical usage ratio

• API content per ODF unit: 0.5 – 2 mg, representing 0.2–0.7% by mass of dried film matrix. Amount varies with polymer system, film dimensions, and pediatric/geriatric dose requirements.

Downstream process integration

• Raw material is dissolved or dispersed in the master solution before casting. Homogeneity validation occurs before casting and after drying-cutting. Final uniformity tests by HPLC or UV assay ensure compliance before packaging.

Final product types

• Orodispersible oral films for at-home, hospice, or nursing facility Parkinson’s management
• Travel-ready, single-dose ODF strips in patient blister packs

3. Injectable Solution Manufacturing for Neurological Use

Several specialty pharmaceutical companies develop parenteral dosage forms for rapid systemic delivery in hospital environments and investigational settings. Process engineering teams integrate this raw material at aseptic compounding stages, using validated sterilization and lyophilization protocols for ready-to-use vials or ampoules. Stringent controls on solvent selection, aseptic filtration, and in-process API stability studies remain essential at manufacturing scale.

Industry compliance standards

• 21 CFR Part 600 (Biologics and Parenterals)
• EU Annex 1 – Manufacture of Sterile Medicinal Products
• USP <797> for compounding sterile preparations
• GMP-GDP for transportation and cold-chain integrity

Typical usage ratio

• Concentration of 0.1 – 2 mg/mL in isotonic solution systems. Volume and mass tailored per therapeutic protocol and clinical trial requirements.

Downstream process integration

• Addition occurs within aseptic compounding suites, immediately prior to sterile filtration and vial filling. Integrity tested by sterility and endotoxin assays post-filling, pre-release to market.

Final product types

• Sterile injectable solutions in glass vials for controlled hospital use
• Single- and multi-dose ampoules for clinical administration under neurologist supervision

4. Research-Grade Bulk API Supply for Clinical Drug Development

CROs, CMOs, and pharmaceutical innovators require kilogram-scale supply of this raw material meeting research and preclinical specification for tox studies and phase I/II clinical batches. Materials undergo analytical verification, elemental impurity profiling, and batch release based on regulatory IND-supporting documentation. Handling adheres to traceability and chain-of-custody mandates for investigational chain submission.

Industry compliance standards

• ICH Q3A/B (Impurities in New Drug Substances/Products)
• 21 CFR Part 312 – Investigational New Drug (IND) Application
• ISO 13408 – Aseptic Processing of Health Care Products
• GLP (Good Laboratory Practice) for non-clinical laboratory studies

Typical usage ratio

• Kilogram to multi-kilogram scale, batch size defined by headcount enrollment in clinical protocols or non-clinical study design, with process verification for scale-up trials.

Downstream process integration

• APIs supplied in sealed, QA-tested primary containers, sampled for method validation, stability, and formulation development in drug product R&D units or pilot GMP suites.

Final product types

• Clinical trial investigational medicinal products (IMP) for phase I/II/III
• Preclinical test articles for pharmacokinetic, toxicology, and analytical method validation studies